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Abstract
 
Background
 
There is an estimate low incidence of patients with Hansen’s disease in Portugal. Following the 1982 World 
Health Organization (WHO) recommendations, extended multidrug therapy (MDT) was started for multibacillary (MB) 
patients. Patients were then treated with rifampicine (RFP), clofazimine (CLF) and dapsone (DDS) for a minimum of 2 years 
or until smear negativity. The aim of this study was to evaluate MDT efficacy in our patient population.
 
Methods
 
Retrospective and descriptive study of 102 MB patients who underwent MDT from 1988 to 2003.
 
Results
 
The number of new MB patients has gradually increased since 1960, the first year of our consultation, due 
mostly to a rise in imported cases. Overall, 34% of the subjects were immigrants, mainly from former Portuguese 
Colonies. Forty-six patients had previously received monotherapy with DDS (mean duration of this treatment, 22 years). 
Relapse after MDT occurred in 9 cases (8.8%), but importantly, all relapsed cases were smear negative at least on one 
occasion after the end of treatment, suggesting these were true relapses rather than treatment failures.
 
Conclusions
 
Despite the 2-year WHO-MDT regimen, patients with MB disease clearly face the possibility of relapse. 
We propose that any reduction in the duration of therapy such as the recently proposed 6-month standard MDT is likely 
to increase the relapse rate even further. Important issues for future consideration are the needs to identify those at risk 
of relapse and in need of alternative antimicrobial treatment with a prolonged clinical follow-up.
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Introduction
 
Hansen’s disease is caused by 
 
Mycobacterium leprae 
 
which causes
selective damage to the skin and peripheral nerves. There is a wide
variety of clinical findings in this disease. In 1966, Ridley and
Jopling created a classification based on polar forms.
 
1
 
 The illness
spectrum ranges from tuberculoid disease to lepromatous disease,
characterized by few skin lesions, and a marked cell-mediated
immune response to the mycobacteria in the former, and multiple
lesions, the greatest number of bacilli and low-immunity in the
latter. Borderline leprosy, as it name implies, has features that are
intermediate between the two ends of the spectrum and refers to
3 forms: borderline lepromatous (BL), borderline-borderline (BB)
and borderline-tuberculosis (BT). Sequelae may be multiple and
variable mainly in late diagnosed and treated patients, affecting
skin, nerves, eyes and musculoskeletal system. The introduction
of dapsone was a major breakthrough in the treatment of Hansen’s
disease. Nevertheless, documentation of primary and secondary
resistance to this drug and to other pharmacological agents led to
the current recommendation that only regularly scheduled com-
bined treatment could prevent resistance and subsequent treatment
failure. Abandoning dapsone monotherapy in 1982, the World
Health Organization (WHO) recommended instead, a minimum
of a 2-year regimen (within stipulated 36 months) of rifampicin
(RFP), dapsone (DDS) and clofazimine (CLF) for cases of multi-
bacillary (MB) Hansen’s disease, continued, wherever possible
until smear negativity.
 
2,3
 
 In 1998, with mounting evidence that less
than 24 months of therapy was effective, recommended duration
was reduced to 1 year.
 
4,5
 
 Significant controversy was recently
generated following a proposal for a reduction in the length of
treatment to 6 months with a standardized MDT regimen for all
Hansen’s disease patients.
 
6
 
Despite the WHO declaration that Hansen’s disease would be
eliminated as a public health problem (defined as a registered
prevalence rate of less than 1 case per 10 000 population) by 2000,
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new cases continue to be diagnosed even outside endemic areas,
 
8,9
 
and the illness remains far from being eradicated.
 
10
 
 Relapse rate is
the single most important measure of MDT efficacy,
 
11
 
 and it
ranges from below 1% to over 20% in various recent studies,
depending upon duration of follow-up, percentage of patients
with a high bacterial burden, type of treatment received, medical
expertise, treatment compliance and the relapse criteria included
in each study.
 
5,8–10,12–14
 
 Unfortunately, there is no clear consensus
in these studies as regards the features which most effectively
identify a relapse. There is currently no WHO recommendation
on follow-up,
 
3
 
 and patients cease to be considered as active cases
in many clinical centres after MB treatment is completed. In a
country with low incidence rates, patients may experience a delay
in referral to a diagnostic centre and also in accurate diagnosis of
relapse. The majority of Hansen’s disease patients in Portugal
are treated at our clinic in the Curry Cabral Hospital in Lisbon
allowing for adequate prompt therapy after diagnoses and for
an accurate diagnosis of relapse. Our consultation is a reference
consultation for this disease and we receive patients from all
Portuguese regions. Additionally, some of these patients came from
a previous leprosarium located in Coimbra region, Leprosaria
Rovisco Pais.
In this study, our purpose was to evaluate MB patients under-
going extended MDT with a particular emphasis on the incidence
of true relapses after adequate therapy.
 
Materials and methods
 
We performed a retrospective, descriptive and analytical study at
Hansen’s disease Consultation in Curry Cabral Hospital. Weekly
appointments by two Dermatology specialists treated Hansen’s
disease patients and their contacts, mainly from central and
 
littoral
 
 regions of Portugal (Fig. 1).
Detailed clinical evaluation included complete dermatological
and neurological examination and all patients were referred to
Ophthalmologic and Ear, Nose and Throat departments during
the first examination. Bacteriological evaluation consisted of nasal
scrapings and skin smears samples every 6 months. Slit-skin smears
were obtained with a scalpel from pinched skin lesions, the earlobe
or other cold skin areas. All smears were sent to the hospital’s micro-
biology department for analysis. Each patient underwent a biopsy of
the skin during the first visit and subsequently, when required. In
some cases, a nerve biopsy was required for diagnosis. Nerve conduction
studies were carried out in the majority of cases. The Ridley-Jopling
classification was used to classify all patients.
The implementation of WHO multidrug therapy (MDT) began
in 1988 with a monthly supervised treatment programme of at
least 2 years or until negative skin smear was obtained: drug
therapy consisted of RFP 600 mg with CLF 300 mg once monthly,
and CLF 50 mg associated to DDS 100 mg daily. Our hospital
control programme consisted in a twice year follow-up for 12 years
after completion of MDT intended to detect delaying reactions,
relapses and prevent disease sequelae. Following this period,
routine evaluation was discontinued but open access to the hospital
clinic was provided whenever required.
In order to evaluate MDT efficacy, retrospective analysis of
clinical records of all subjects (both ‘new’ and ‘old’ patients) was
undertaken after the introduction of MDT and until 2005 (in
order to include a 2-years follow-up of those patients treated up to
2003). Of the 292 patients detected during this period, the majority
had MB forms (230 patients). Of these MB forms, 118 were not
selected to initiate MDT because they were ‘old’ patients that had
already undergone a period of treatment with DDS in excess of 20
years. MDT was started on a total of 112 patients. Among these
112 patients, 102 MB patients concluded extended-MDT, with five
patients either lost to follow-up or non-compliant with regular
therapy. Adverse reactions to rifampicine were responsible for the
complete interruption of this drug in the other five cases: three
patients had a ‘flu-like’ syndrome and two patients developed
renal failure (Table 1; data previously reported).
 
15
 
The following were studied in the 102 MB patients treated
with extended MDT: demographic data (age, gender, country
and city of origin, current residence), time between onset of initial
Figure 1 Main prevalence regions for Hansen’s Disease in Portugal.
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symptoms and start of therapy, clinical presentation, previous
monotherapy with dapsone and its duration, bacterial index (BI)
before and after extended-MDT, treatment duration until smear
negativity, clinical reactions and their management, relapses,
bacterial index and histopathologic diagnosis at the relapse,
characteristics of lesions on relapses, presence of sequelae (ocular,
otorrinolaringologic, neurological and bone) and duration of
follow-up.
Relapse was defined as patients remaining symptom-free after
MDT until smear negativity but developing:
• Skin and/or nerve lesions clinically and/or histopathologically
consistent with active Hansen’s disease using the Ridley-
Jopling classification.
 
1
 
• BI of 2
 
+
 
 in one or more smear sites.
 
Statistical analysis
 
Continuous variables were tested for normal distribution with
normality tests (Shapiro-Wilk if 
 
<
 
 50 cases, Kolmogorov-Smirnov
if 
 
≥
 
 50 cases). Most continuous variables had a non-parametric
distribution. Bivariate analysis between independent and dependent
variables was made using non-parametric tests: Spearman’s corre-
lation analysis for continuous variables, two-tailed chi-squared
test with Yates correction and Fisher’s exact test, whenever
applicable, for categorical variables and Mann-Whitney’s test to
compare categorical and numerical variables.
Quantitative and qualitative data of baseline characteristics of
population were expressed as median [1st–3rd quartiles] or mean
 
±
 
 standard deviation (SD) and percentage (95% confidence inter-
vals, 95% CI), respectively.
Bivariate analysis was made using Kaplan-Meier and logrank
test: relapse survival rates were compared between groups (sex,
bacillary skin index 
 
≤
 
/
 
> 
 
2, previous DDS therapy and steroid
therapy of reactions), as well as mean survival time and 95% CI.
P-values less then 0.05 were considered statistically significant.
Data from each case were recorded on standardized report
forms, entered into a database and analysed using SPSS software
13.0 for Windows® (SPSS Inc., Chicago, IL).
 
Results
 
The 102 MB patients were registered at our clinic between 1968
and 2003 and the year of diagnosis ranged between 1934 and 2003.
The number of Hansen’s disease patients increased in recent years
(Fig. 2).
Table 2 provides the major baseline characteristics of our
cohort, comparing patients with relapse vs. those without relapse.
Table 1 Adverse reactions to monthly Rifampicin schedule in the treatment of leprosy (n = 5 cases).15
Case Sex Age Clinical
form
Therapy
duration
Clinical manifestations Adverse reactions Treatment
1 F 65 BL 4 Nausea, abdominal pain, fever, jaundice ARF, Haemolysis, DIC Haemodialysis RFP interruption
2 F 54 BT 11 Nausea, oliguria ARF Haemodialysis RFP interruption
3 F 65 BL 20 Fever, myalgias, chills, headaches ‘flu-like’ syndrome RFP interruption
4 F 61 LL 12 Fever, myalgias, chills, headaches ‘flu-like’ syndrome RFP interruption
5 F 49 LL 13 Fever, myalgias, chills, headaches ‘flu-like’ syndrome RFP interruption
ARF, Acute renal failure; DIC, disseminated intravascular coagulopathy.
Figure 2 Hansen’s disease year of diagnosis (n = 102).
Table 2 Patients baseline characteristics
Relapse
(n = 9)
No relapse
(n = 93)
P-value
Median [Q1–Q3]
Age at diagnosis 27 [20–49] 30 [24–53] P > 0.05
Age at start MDT 55 [37–64] 55 [36–62] P > 0.05
n (%)
Male gender 3 (33.3) 51(54.8) P > 0.05
Clinical form
LL 5 (55.6) 63 (67.7) P > 0.05
BL 4 (44.4) 30 (32.2) P > 0.05
Steroid therapy 6 (66.7) 25 (26.8) P > 0.05
Previous DDS therapy 3 (33.3) 38 (40.9) P > 0.05
BI ≥ 4 2 (22.2) 24 (25.8) P > 0.05
Non Portuguese 3 (33.3) 33 (35.5) P > 0.05
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Of the 102 patients followed up, 52.9% were male with a mean
age of diagnosis of 30.5 years. Sixty-six (65.3%) were Portuguese
and 36 foreigners (34.7%): 11 patients from Brazil (mainly from
the states of Goiás and Minas Gerais), 11 from Angola, 8 from
Cape Verde, 4 from East Timor, one from India and another one
from Guinea-Bissau (Table 3).
Thirty patients already had a family history of the disease. Two-
hundred and ninety-nine (299) contacts of the 102 patients were
observed, but only one with an indeterminate form of Hansen’s
disease was diagnosed.
Time elapsed between the onset of Hansen’s disease symptoms
and diagnosis had a median of 12 months ranging from 5 to
36 months. In 74.2% of patients, it was less than 24 months, and
the maximum interval registered was 22 years.
Using the Ridley-Jopling classification, 68 patients were classi-
fied as having a lepromatous form of the disease and 34 patients
as borderline lepromatous. The majority of patients (74.5%) had
reduced BI (
 
≤
 
 3
 
+
 
) in mucous and skin smear prior to MDT.
Forty-one subjects (40.9%) had been previously treated with
DDS monotherapy for varied periods, and the mean duration of
therapy was 22 years [13.3–28.5] with the longest period of previous
DDS monotherapy being 36 years. Earlier monotherapy had a high
association with a lower bacillary index (
 
P
 
 
 
<
 
 0.0001) before MDT.
In 45% of cases, MDT duration was for 2 years, and in 34·3% of
cases, it exceeded 2 years but was less than 5 years. In 20.6% of
cases, MDT was more than 5 years. Median therapy duration was
29 months [IQ 24–60]. The longest period of treatment was
10 years in three cases. Duration of MDT until smear negativity
was below 24 months in 74.1% of cases, and the longest period of
time until negative testing was 96 months (Fig. 3).
MDT duration until smear negativity was not influenced by
previous DDS therapy (
 
P
 
 
 
=
 
 0.369) nor by duration of current one
(
 
P
 
 
 
=
 
 0.837, rho 
 
=
 
 0.034). But the association between initial bacte-
riological index and the duration of MBT up to BI negativity
(
 
P
 
 
 
=
 
 0.0001, rho 
 
=
 
 0.716) was statistically significant. Fig. 4 shows
that patients with higher BI before MDT were associated with
longer periods of therapy until smear negativity with the inverse
applying to lower BI cases.
In what concerns follow-up, three patients were followed to
death (1, 10 and 17 years after MDT completion) and 31 patients
completed the 12-year biannual follow-up. The mean follow-up
time for all patients was 5.5 years,
 
2–8
 
 with 74 patients followed
after 2000 and 40 patients were still in follow-up in the year 2005.
Table 3 Demographic distribution of patients
Portuguese Foreigner
Main district Number of
patients
Country Number of
patients
Setúbal 9 Brazil 11
Coimbra 9 Angola 11
Santarém 8 Cape Verde 8
Viseu 7 East Timor 4
Castelo Branco 6 India 1
Vila Real 5 Guinea-Bissau 1
Faro 4
Lisboa 4
Beja 4
Leiria 3
Braga 3
Bragança 2
Viana Castelo 1
Azores islands 1 Figure 3 Time to smear negativity with MDT (months).
Figure 4 Relation between initial BI and the duration of MDT until 
smear negativity (thick bars represent mean, upper and lower lines 
of the boxes represent IQR: percentile 75 and 25).
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Reactions
 
Reactions occurred in 41 subjects:
• Twenty-one patients had reversal reactions (15 cases were
classified as an upgrading reaction and 6 cases as a down-
grading reaction).
• Twenty patients had erythema nodosum leprosum.
In 29 patients (70.7%), reaction occurred after initiation of MDT
and in 12 patients (29.3%) before MDT. In the post-therapeutic
reaction group, this episode occurred in 96%
 
16
 
 cases within
24 months after initiation of MDT.
Previous monotherapy was significantly associated with fewer
reactions (25% with DDS, 49.1% without DDS, 
 
P
 
 
 
=
 
 0.02, two-tailed
Fisher exact test).
Thirty-one patients were treated exclusively with corticosteroids
(
 
n
 
 
 
=
 
 17) or in association with non-steroidal anti-inflammatory
drugs (
 
n
 
 
 
=
 
 5), thalidomide (
 
n
 
 
 
=
 
 7) or pentoxifiline (
 
n
 
 
 
=
 
 2). One patient
was treated only with non-steroidal anti-inflammatory drugs and
thalidomide was the only drug used with nine cases.
 
Sequelae
 
The majority of patients presented sequelae: 96% with neurological
(nerve enlargement, ‘papal hand’ and ‘claw hand’ flexion, sensory-
motor neuropathy, foot drop); 29.7% with otorrinolaringologic
(‘saddle nose’, rhinitis, anosmia) and 36.6% with osseous sequelae
(bone resorption, neurotrophic ulcers). Ocular sequelae (lagoph-
talmos, keratitis, episclerites or blindness) occurred in 12.9% of
patients.
There was no statistical correlation between previous medi-
cation with DDS and the appearance of sequelae (Chi-squared
test, 
 
P
 
 
 
=
 
 0.81).
 
Relapses
 
Relapses occurred in nine cases (8.8%) without significant com-
orbidity (Table 2). Six patients were Portuguese, two Brazilian
and one Angolan. All patients with relapse had zero BI on MDT
completion, indicating that these are relapsed cases rather than
treatment failures. Five cases were classified as having an LL
form and four cases were BL. The female/male ratio was 3 : 1. Age
of relapsed patients ranged from 20 to 72 years at the beginning
of treatment without predominance of any single age group.
Relapsed cases were treated with mean MDT duration of 3.3 years
[IQ 2–4]. The duration between end of treatment and relapse
varied from 24 months to 11.5 years, with the mean of this period
for all patients being 5 years [IQ 3–8.9].
Skin and mucous smear at onset and on relapse were available
in all cases. BI detected in these patients prior to MDT was not
high: in five cases the highest BI recorded in skin or mucous
smear was between 2
 
+
 
 and 3
 
+
 
, with other patients presenting
values between 4
 
+
 
 and 6
 
+
 
, with BI at relapse similar to levels
before treatment.
Relapsed patients most commonly presented maculo-papular
type lesions. Plaques and papules were seen in four cases. These
clinical manifestations could be closely compared at the onset of
MDT.
No association was observed between relapse and previous
DDS therapy (
 
P 
 
=
 
 
 
0.29).
Relapse cases were not associated with peripheral neuropathy
or disability and we also found that risk of relapse was similar both
for those who were administered steroids during treatment and
those who were not (
 
P 
 
=
 
 
 
0.577).
To compare groups regarding relapse rates bivariate analysis
was made using Kaplan-Meier and log-rank test (Table 4): relapse
survival rates were compared between groups (sex, bacillary skin
index 
 
≤
 
/
 
>
 
 2, previous DDS therapy and steroid therapy for
reactions). From the comparative factors studied, only bacillar
index 
 
≤
 
 2 (
 
P
 
 
 
=
 
 0.014) and previous DDS therapy (
 
P
 
 
 
=
 
 0.049) were
statistically associated with a more prolonged time until relapse
(Figs 5 and 6).
 
Discussion and conclusions
 
A comparison between this study and an earlier one conducted at
the Curry Cabral Hospital between 1980 and 1899
 
17
 
 shows that
imported new cases of the disease have increased in the past few
years. While in the earlier study, imported cases represent 23% of
the total number, in the present study, these contribute with 34%.
This comparison with the previous study also revealed a shift in
imported patient origin from African Speaking African Countries
to Brazil, coinciding with the major waves of immigration into the
country over the past years. The majority of Portuguese patients
continue to originate from central coastal regions. We conclude
that Portugal has a low incidence of Hansen’s disease with a
Figure 5 Relapse-free survival curves in patients with bacillary skin 
index ≤ 2 and > 2. The difference in relapse times between the two 
groups was statistically significant (P = 0.014).
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significant contribution from immigration. As a result, national
awareness of the disease is poor and early diagnosis and identifi-
cation of relapse continue to present significant challenges.8,9
In comparing the subgroup of DDS patients with new cases
beginning MDT, it is interesting to note that monotherapy and
its duration had no influence on the period necessary to reach
smear negativity after MDT initiation. As previously documented
in a study at Karigiri Hospital in India,13 it also had no impact
on the appearance of sequelae or relapses. Monotherapy was, on
the other hand, significantly associated with fewer reactions and
a lower initial BI (before start of MDT).
Also of statistical significance was the relationship between the
bacteriological index and the duration of MBT up to BI negativity.
Another notable finding was that despite initiation of MDT in our
patients, we continued to observe severe reaction episodes and
sequelae and that 25·9% of our patients were smear positive even
after 24 months of MDT.
Growing evidence suggest that a high initial BI is associated with
elevated subsequent relapse rates.12,14,18 Although our relapse rate
was high (8.8%), our patients did not present a high initial bacterial
load, being the relapse rate similar for LL or BL, in accordance to
published reports for both subgroups.14,18 Gelber et al. suggested
that males could have as much as twice the risk of relapse compared
to females.12 Conversely, we found that in the group of relapses
only 3 patients were males. The risk of relapse, in both studies, was
the same for those given steroids during treatment and those that
were not. Additionally, in the relapse survival rates comparison
we found that bacilar index ≤ 2 and previous DDS therapy were
statistically associated with a more prolonged time until relapse.12
The elapsed time after extended MDT for relapses varied from
24 months to 11.5 years, with a mean of 5.8 ± 3.6 years. According
to other studies, a follow-up of seven to 10 years is more appropriate
for drawing final conclusions on relapse rates.13 As our follow-up
time was relatively short, we consider that continuation of this study
may reveal an increased relapse rate.
Our present findings and earlier studies show that attaining
smear negativity is not a guarantee of absence of future progressive
relapse.13,14,18 Relapse cases may be either due to persistent micro-
organisms or to re-infection;19 therefore, in the absence of any
method to prove re-infection and in a low-incidence country, it is
reasonable to assume that the nine reported cases are persisters.
While we acknowledge that early WHO’s treatment strategies
have given better access to the diagnosis of Hansen’s disease, with
more than 10 million patients treated and free of charge MDT drugs
now,10,20 we believe that the recent WHO’s policy of considering
this disease as a health problem which has been almost entirely
eliminated, has encouraged countries to further reduce vital invest-
ment and research into this pathology10,20,21 and waned enthusiasm
for vaccines research.20
Table 4 Influence of sex, skin bacillar index, previous DDS therapy, and corticotherapy for reactions in respect to survival time to relapse
(Kaplan-Meier survival estimates)
Comparative factor Comparative
levels
Mean for survival time to relapse Cumulative proportion surviving 
at the time (Kaplan-Meier estimates)
P-value 
(log-rank test)Estimate 95% CI
Lowerbound Upper bound 1 year 2 years 5 years 10 years
Sex Male 170.552 145.964 195.139 0.978 0.923 0.686 0.686
Female 160.891 136.034 185.748 0.980 0.952 0.714 0.714 0.347
Skin bacillar index ≤ 2 181.283 165.386 197.180 0.979 0.979 0.979 0.857
≥ 3 115.697 97.095 134.300 0.976 0.864 0.864 0.691 0.014
Previous dapsone therapy Yes 180.035 163.083 196.987 0.971 0.861 0.861 0.861
No 118.849 103.117 134.581 0.960 0.930 0.000 0.000 0.049
Corticotherapy Yes 131.570 92.041 171.099 0.933 0.837 0.777 0.777
No 143.750 122.957 164.543 0.750 0.750 0.750 0.750 0.292
Figure 6 Relapse-free survival curves in patients with or without 
previous DDS therapy. The difference in relapse times between the 
two groups was statistically significant (P = 0.049).
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MDT duration was, in our study, over 2 years in 55% of cases.
In our opinion, the 24 months treatment duration proposed by
the WHO may be insufficient, and it is probably not appropriate
to reduce this period further to the proposed six-month standard
MDT.10 There have also been various recently reported cases of
multidrug-resistant strains of M. leprae.16,22–25 Despite the success
of WHO-MDT, patients with MB disease are clearly at risk of
relapse. In our opinion, there’s still a need to identify those at risk,
to improve infrastructures for long-term follow-up and also to
develop effective and more appealing therapies for MB Hansen’s
disease.3,5,21
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